期刊文献+

Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma 被引量:4

Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma
下载PDF
导出
摘要 Transcatheter arterial chemoembolization(TACE) is an effective palliative intervention that is widely accepted for the management of hepatocellular carcinoma(HCC). Post-TACE pulmonary complications resulting in acute lung injury(ALI) or acute respiratory distress syndrome(ARDS) are rare events. Pulmonary complications after TACE are thought to be related to chemical injury subsequent to the migration of the infused ethiodized oil or chemotherapeutic agent to the lung vasculature, facilitated by arteriovenous(AV) shunts within the hyper-vascular HCC. We review herein the literature on pulmonary complications related to TACE for HCC. Post-TACE pulmonary complications have included pulmonary oil embolism, interstitial pneumonitis, chemical pneumonitis, ALI, ARDS, lipoid pneumonia, acute eosinophilic and neutrophilic pneumonia, bilious pleuritis, pulmonary abscess, pulmonary tumor embolism, and possibly pulmonary metastasis with HCC. The risk factors associated with post-TACE pulmonary complications identified in the literature include large hyper-vascular HCC with AV shunts, large-volume Lipiodol infusion, and embolization via the right inferior phrenic artery. However, the absence of known risk factors is not a guarantee against serious complications. An astute awareness of the potential post-TACE pulmonary complications should expedite appropriate therapeutic interventions and increase potential for early recovery. Transcatheter arterial chemoembolization(TACE) is an effective palliative intervention that is widely accepted for the management of hepatocellular carcinoma(HCC). Post-TACE pulmonary complications resulting in acute lung injury(ALI) or acute respiratory distress syndrome(ARDS) are rare events. Pulmonary complications after TACE are thought to be related to chemical injury subsequent to the migration of the infused ethiodized oil or chemotherapeutic agent to the lung vasculature, facilitated by arteriovenous(AV) shunts within the hyper-vascular HCC. We review herein the literature on pulmonary complications related to TACE for HCC. Post-TACE pulmonary complications have included pulmonary oil embolism, interstitial pneumonitis, chemical pneumonitis, ALI, ARDS, lipoid pneumonia, acute eosinophilic and neutrophilic pneumonia, bilious pleuritis, pulmonary abscess, pulmonary tumor embolism, and possibly pulmonary metastasis with HCC. The risk factors associated with post-TACE pulmonary complications identified in the literature include large hyper-vascular HCC with AV shunts, large-volume Lipiodol infusion, and embolization via the right inferior phrenic artery. However, the absence of known risk factors is not a guarantee against serious complications. An astute awareness of the potential post-TACE pulmonary complications should expedite appropriate therapeutic interventions and increase potential for early recovery.
出处 《World Journal of Respirology》 2016年第3期69-75,共7页 世界呼吸病学杂志
基金 Supported by NIH 4KL2TR001112(to Quan M Nhu)
关键词 TRANSCATHETER arterial CHEMOEMBOLIZATION Liver cirrhosis PULMONARY complications Hepatocellular carcinoma ACUTE lung injury ACUTE respiratory distress syndrome PNEUMONITIS PULMONARY oil EMBOLISM Transcatheter arterial chemoembolization Liver cirrhosis Pulmonary complications Hepatocellular carcinoma Acute lung injury Acute respiratory distress syndrome Pneumonitis Pulmonary oil embolism
  • 相关文献

参考文献2

二级参考文献28

  • 1Hsieh MY, Chang WY, Wang LY, Chen SC, Chuang WL, Lu SN, Wu DK. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. Cancer Chemotherapy & Pharmacology 1992; 31:S82-85.
  • 2Yoshimi F, Nagao T, Inoue S, Kawano N, Muto T, Gunji T,Ohnishi S, Imawari M. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial. Hepatolology 1992; 16:702-706.
  • 3Bonfil RD, Bustuoabad OD, Ruggiero RA, Meiss RP, Pasqualini CD. Tumor necrosis can facilitate the appearance of metastasis.Clin Exp Metastasis 1988; 6:121-129.
  • 4Lee YT, Geer DA. Primary liver cancer: pattern of metastasis. J Surg Oncol 1987; 36:26-31.
  • 5Liou TC, Shih SC, Kao CR, Chou SY, Lin SC, Wang HY. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol 1995; 23:563-568.
  • 6Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977;35:1-39.
  • 7Hashimoto N, Kobayashi M, Tsuji T. Serum type IV collagendegrading enzyme in hepatocellular carcinoma with metastasis.Acta Med Okatlama 1988: 42:1-6.
  • 8Isoai A, Giga-Hama Y, Shinkai K, Mukai M, Akedo H, Kumagai H. Tumor invasion-inhibiting factor 2: primary structure and inhibitory effect on invasion in vitro and pulmonary metastasis of tumor cells. Cancer Res 1992; 52:1422-1426.
  • 9Boix L, Bruix J, CasteUs A. Circulating mRNA for alpha-fetopro-tein in patients with hepatocellular carcinoma. Evidence of tumor dissemination after transarterial embolization. Hepatology1996; 24:349.
  • 10Peters RL. Pathology of hepatocellular carcinoma. Okuda K,Peters, RL, eds. Hepatocellular carcinoma. New York: John Wiley Son Inc, 1976:107-168.

共引文献21

同被引文献61

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部